Last time the analysts gave a positve view on sp, within a short time the price virtually doubled.
Not suggesting that this will happen in the short term as we do not at this stage have a pandemic situation with influenza.
However the cirmustances are now quite different for BTA in terms of ROW for Inavir and other activity within their pipeline developments perhaps.